Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of November 10, 2026, KLRS trades at $2.31 with a market cap of $57.61M and a P/E ratio of 0.00. KLRS moved +0.22% today. Year to date, KLRS is -71.31%; over the trailing twelve months it is -49.87%. Its 52-week range spans $1.78 to $12.90. Analyst consensus is strong buy with an average price target of $15.50. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks KLRS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $2.31 |
| Market Cap | $57.61M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $1.78 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover KLRS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.50.